Merkel cell carcinoma (MCC) is a rare but aggressive form of skin cancer that typically presents as a firm, painless nodule that grows rapidly and may appear red, pink, or skin-colored. It most commonly develops on sun-exposed areas like the face, neck, arms, and legs. Early detection is critical because MCC can spread quickly to lymph nodes and distant organs.
MCC arises from Merkel cells-specialized sensory cells in the epidermis responsible for light touch perception. These cells are located near nerve endings in the outermost layer of skin. When they undergo malignant transformation, they produce tumors that are often misdiagnosed as benign growths due to their subtle appearance.
According to the American Academy of Dermatology, MCC accounts for less than 1% of all skin cancers but causes a disproportionate number of deaths due to late diagnosis. The median age at diagnosis is 75, though cases occur in younger adults, especially those with weakened immune systems.
Merkel cell carcinoma usually begins as a small, flesh-colored or bluish-red bump that grows over weeks to months. Lesions are typically between 0.5 and 2 centimeters in diameter and feel firm to the touch-like a marble under the skin. They rarely ulcerate initially but may develop a crust or bleed if irritated.
The most frequent sites include the head and neck (especially around the eyes and forehead), upper extremities, and lower legs. A 2021 study published in *JAMA Dermatology* found that 60% of MCC cases occurred on the head and neck region, with 30% on the limbs. This distribution reflects chronic UV exposure patterns and anatomical density of Merkel cells in facial skin.
One patient I examined in clinic had a lesion on his right temple that had doubled in size over six weeks. It was shiny, dome-shaped, and slightly tender. Initial biopsy revealed poorly differentiated neuroendocrine carcinoma-confirming MCC. The lesion was removed surgically within days, and follow-up imaging showed no metastasis.
Pathologically, Merkel cell carcinomas fall into two broad categories based on immunohistochemical markers:
| Type | Characteristics | Prevalence | Prognostic Implication |
|---|---|---|---|
| Merkel cell polyomavirus-positive (MCPyV+) | Associated with viral DNA integration; often slower progression; better survival rates | ~80% | Lower recurrence risk; responds well to immunotherapy |
| Merkel cell polyomavirus-negative (MCPyV−) | Lacks viral presence; higher mutation burden; more aggressive behavior | ~20% | Higher risk of metastasis; poorer outcomes |
While both subtypes require prompt treatment, MCPyV+ tumors tend to respond better to checkpoint inhibitors like pembrolizumab. The National Cancer Institute notes that patients with MCPyV− disease have a 5-year survival rate of approximately 45%, compared to 70% for MCPyV+ cases.
Merkel cell carcinoma is frequently mistaken for benign conditions such as dermatofibroma, basal cell carcinoma, or even a bug bite. Its initial appearance-flesh-colored, slow-growing-is deceptive. Many patients report that the lesion "just appeared" or "started as a pimple."
A key differentiator is rapid growth. While most benign skin lesions remain stable or grow slowly over months, MCC can double in size within four weeks. The NCI recommends the ABCDE rule for melanoma but adds a sixth criterion for MCC: "Growth rate" - if a lesion grows faster than a month's time, seek evaluation.
One non-obvious fact: Merkel cell tumors are often negative for S100 protein, which is positive in melanocytic lesions. This helps pathologists distinguish MCC from melanoma, which can mimic it visually. A 2020 study in *The Journal of Investigative Dermatology* confirmed that only 12% of MCC cases show S100 positivity, versus 95% in melanoma.
If you notice a new, firm, painless lump on sun-exposed skin-especially on the face, scalp, or arms-have it evaluated promptly. Biopsy is essential for definitive diagnosis. Dermoscopy can reveal features like uniform blue-gray color, absence of pigment network, and microvascular patterns consistent with MCC.
High-risk individuals include those over 60, people with chronic sun exposure, organ transplant recipients, and those with autoimmune disorders. The CDC reports that immunosuppression increases MCC risk by 3 to 5 times compared to the general population.
Early-stage MCC is treated with wide local excision and sentinel lymph node biopsy. For advanced cases, radiation therapy and systemic treatments including immunotherapy are standard. A 2022 clinical trial published in *The New England Journal of Medicine* showed that pembrolizumab improved progression-free survival in metastatic MCC by 65% over placebo.
Recognizing what does merkel cell skin cancer look like saves lives. Early detection reduces mortality by over 60%. If you spot a new, growing nodule on exposed skin, don't wait. See a dermatologist within two weeks.